List of Tables
Table 1. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Gene Cell Therapy CDMO Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Gene Cell Therapy CDMO Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Gene Cell Therapy CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Gene Cell Therapy CDMO Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Gene Cell Therapy CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Cell Therapy CDMO as of 2024)
Table 11. Global Gene Cell Therapy CDMO Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Gene Cell Therapy CDMO Companies Headquarters
Table 13. Global Gene Cell Therapy CDMO Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Gene Cell Therapy CDMO Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Gene Cell Therapy CDMO Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Gene Cell Therapy CDMO Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Gene Cell Therapy CDMO Revenue by Application (2026-2031) & (US$ Million)
Table 21. Gene Cell Therapy CDMO High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Gene Cell Therapy CDMO Growth Accelerators and Market Barriers
Table 25. North America Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Gene Cell Therapy CDMO Growth Accelerators and Market Barriers
Table 27. Europe Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Gene Cell Therapy CDMO Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Gene Cell Therapy CDMO Investment Opportunities and Key Challenges
Table 31. Central and South America Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Gene Cell Therapy CDMO Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Catalent Corporation Information
Table 35. Catalent Description and Major Businesses
Table 36. Catalent Product Features and Attributes
Table 37. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Catalent Revenue Proportion by Product in 2024
Table 39. Catalent Revenue Proportion by Application in 2024
Table 40. Catalent Revenue Proportion by Geographic Area in 2024
Table 41. Catalent Gene Cell Therapy CDMO SWOT Analysis
Table 42. Catalent Recent Developments
Table 43. Lonza Corporation Information
Table 44. Lonza Description and Major Businesses
Table 45. Lonza Product Features and Attributes
Table 46. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Lonza Revenue Proportion by Product in 2024
Table 48. Lonza Revenue Proportion by Application in 2024
Table 49. Lonza Revenue Proportion by Geographic Area in 2024
Table 50. Lonza Gene Cell Therapy CDMO SWOT Analysis
Table 51. Lonza Recent Developments
Table 52. Thermo Fisher Corporation Information
Table 53. Thermo Fisher Description and Major Businesses
Table 54. Thermo Fisher Product Features and Attributes
Table 55. Thermo Fisher Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Thermo Fisher Revenue Proportion by Product in 2024
Table 57. Thermo Fisher Revenue Proportion by Application in 2024
Table 58. Thermo Fisher Revenue Proportion by Geographic Area in 2024
Table 59. Thermo Fisher Gene Cell Therapy CDMO SWOT Analysis
Table 60. Thermo Fisher Recent Developments
Table 61. ACG Biologics Corporation Information
Table 62. ACG Biologics Description and Major Businesses
Table 63. ACG Biologics Product Features and Attributes
Table 64. ACG Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. ACG Biologics Revenue Proportion by Product in 2024
Table 66. ACG Biologics Revenue Proportion by Application in 2024
Table 67. ACG Biologics Revenue Proportion by Geographic Area in 2024
Table 68. ACG Biologics Gene Cell Therapy CDMO SWOT Analysis
Table 69. ACG Biologics Recent Developments
Table 70. Charles River Corporation Information
Table 71. Charles River Description and Major Businesses
Table 72. Charles River Product Features and Attributes
Table 73. Charles River Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Charles River Revenue Proportion by Product in 2024
Table 75. Charles River Revenue Proportion by Application in 2024
Table 76. Charles River Revenue Proportion by Geographic Area in 2024
Table 77. Charles River Gene Cell Therapy CDMO SWOT Analysis
Table 78. Charles River Recent Developments
Table 79. Oxford Biomedica Corporation Information
Table 80. Oxford Biomedica Description and Major Businesses
Table 81. Oxford Biomedica Product Features and Attributes
Table 82. Oxford Biomedica Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Oxford Biomedica Recent Developments
Table 84. Novartis Corporation Information
Table 85. Novartis Description and Major Businesses
Table 86. Novartis Product Features and Attributes
Table 87. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Novartis Recent Developments
Table 89. OBiO Corporation Information
Table 90. OBiO Description and Major Businesses
Table 91. OBiO Product Features and Attributes
Table 92. OBiO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. OBiO Recent Developments
Table 94. GenScript Corporation Information
Table 95. GenScript Description and Major Businesses
Table 96. GenScript Product Features and Attributes
Table 97. GenScript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. GenScript Recent Developments
Table 99. Pharmaron Corporation Information
Table 100. Pharmaron Description and Major Businesses
Table 101. Pharmaron Product Features and Attributes
Table 102. Pharmaron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Pharmaron Recent Developments
Table 104. Porton Corporation Information
Table 105. Porton Description and Major Businesses
Table 106. Porton Product Features and Attributes
Table 107. Porton Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Porton Recent Developments
Table 109. Raw Materials Key Suppliers
Table 110. Distributors List
Table 111. Market Trends and Market Evolution
Table 112. Market Drivers and Opportunities
Table 113. Market Challenges, Risks, and Restraints
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Cell Therapy CDMO Product Picture
Figure 2. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Immune Cells Product Picture
Figure 4. Stem Cell Product Picture
Figure 5. Viral Vector Product Picture
Figure 6. Plasmid DNA Product Picture
Figure 7. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Pharmaceutical and Biotechnology Companies
Figure 9. Research and Academic Institutions
Figure 10. Hospital
Figure 11. Others
Figure 12. Gene Cell Therapy CDMO Report Years Considered
Figure 13. Global Gene Cell Therapy CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 15. Global Gene Cell Therapy CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Gene Cell Therapy CDMO Revenue Market Share by Region (2020-2031)
Figure 17. Global Gene Cell Therapy CDMO Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Immune Cells Revenue Market Share by Player in 2024
Figure 20. Stem Cell Revenue Market Share by Player in 2024
Figure 21. Viral Vector Revenue Market Share by Player in 2024
Figure 22. Plasmid DNA Revenue Market Share by Player in 2024
Figure 23. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2020-2031)
Figure 24. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2020-2031)
Figure 25. North America Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 27. North America Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 34. Europe Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 37. France Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 49. India Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 57. Central and South America Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 63. South America Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 69. Gene Cell Therapy CDMO Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
